Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

nt to EUR 5.4 million, a decrease of 5% compared to the EUR 5.6 million achieved in 2006. At constant exchange rate, total revenues would have increased 4% between 2006 and 2007. 89% of ExonHit's 2007 revenues come from the Allergan collaboration; this compares with 76% in 2006. While revenues generated by the Therapeutics and SpliceArray(TM) activities posted double-digit growth in 2007, revenues form the bioMerieux collaboration decreased due to, on the one hand, the delays experienced in the recruitment of samples in prostate cancer and, on the other hand, the milestone achieved in 2006 in this collaboration.

R&D revenues from grants increased from EUR 0.01 million in 2006 to EUR 0.05 million in 2007.

R&D expenses have increased by 27% to EUR 8.6 million in 2007 when compared to EUR 6.8 million in 2006, mainly as a result of increased expenses in clinical trials. In 2007, R&D revenues covered 62% of the company's R&D expenses, as opposed to 83% in 2006.

Marketing and selling expenses have increased by 31% to EUR 1.0 million in 2007, compared to EUR 0.8 million in 2006. This increase mainly comes from the recruitment of new employees in this department and the increase in the selling and marketing effort for SpliceArray(TM).

General and administrative costs increased by 16% to EUR 3.5 million in 2007, compared to EUR 3.0 million in 2006. This increase mainly comes from the substantial increase of study and consultancy fees between the two years as a result of increased expenses to value our IP.

Operating expenses have been increased by 24% to EUR 13.2 million in 2007 compared to EUR 10.6 million in 2006. In 2007, 65% of these expenses are allocated to R&D compared to 64% in 2006.

Consequently, the company posted an operating loss of EUR 7.8 million in 2007, compared to EUR 5.0 million in 2006.

The presence of convertible bonds throughout fiscal year 2007, as well as the leasing of some pieces of equipment, explains
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/25/2014)... The report “Service Quality Management and ... Provider Type - Global Advancements, Worldwide Forecasts & Analysis ... analysis and forecasting of revenues. , Browse 152 ... and in-depth TOC on “Service Quality Management (SQM) and ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the "Company"), ... of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Technologies, Inc. announced this week that it has finalized ... in Avegno for exclusive distribution rights of the AcceleDent™ ... AcceleDent™ System is currently being sold outside the USA ... The lightweight appliance, used to speed up the rate of orthodontic ...
... New York, November 21, 2011 New Report ... to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures ...   Published by  GBI Research . ... to 2017 - Glaucoma and Cataract Surgery Devices, Minimally ...
... 21, 2011 The report " ... Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 ... major market drivers, restraints, and opportunities in North America, ... tables and in-depth TOC on Leukemia Therapeutics Market (Acute/Chronic ...
Cached Biology Technology:OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy 2OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy 3ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 2ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 3ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 4MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... that crystals form the basis for the penetrating icy blue glare ... solar energy technology? Crystals are at the heart of diodes. ... manufactured to form alloys, such as indium gallium nitride or InGaN. ... in the visible range, and of laser diodes (LDs) in the ...
... Ore. -- (Oct. 25, 2013) -- Twenty grams of essential amino ... weeks after knee-replacement surgeries helped 16 patients, mean age 69, recover ... ingesting a placebo. The approach -- detailed in a paper ... the Journal of Clinical Investigation -- could spell relief ...
... the region? A recent study, published in the open access ... obtain empirical data on the activity and distribution of the ... of Fiji and examine its association with the invasive creeping ... the invasive creeping daisy could in fact have a positive ...
Cached Biology News:ASU, Georgia Tech create breakthrough for solar cell efficiency 2Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4Angel or demon: Can a potentially invasive plant bring a positive influence to a region? 2
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
... The Caliper Sciclone ALH 3000 workstation ... diagnostic applications, from Genomic and Proteomic Sample ... Assays. The modular design of the ... options and accessories to perfectly meet the ...
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... Workstation from Caliper represents a revolutionary breakthrough ... first time the ability to generate real-time ... changing conditions. In addition, each channel ... to changes in temperature, and offers its ...
Biology Products: